Recurrence rate after surgery of superfidal bladder cancer was still very high without additional treabnent. Currently, Badllus Calmette-Guerin (BCG) is widely used in the treatment against recurrence in superficial bladder cancer. Objective: To evaluate the initial results of prophylatic adjuvant Bacille Calmette-Guerin therapy in superfidal bladder cancer after transurethral resection. Patients and Methods: prospective longitudinal follow-up non controlled study on 33 bladder cancer patients stage Tis, T1, Ta; grade 2 or 3 at department of oncology of 108 military central Hospital from 2/2012 to 12/2013. Results: The complete response at 4 months and 12 months after TUR was 91 percent and 87.8 percent respectively, non complete responses was 9 percent. Mean Recurrence time was 31,08 months. Cumulative recurrence rate at 2 years was 12.1 percent.
- Đăng nhập để gửi ý kiến